Patents by Inventor Mary E. Yacyshyn

Mary E. Yacyshyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11946927
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: April 2, 2024
    Inventors: Bruce R. Yacyshyn, Mary E. Yacyshyn
  • Patent number: 11199534
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: December 14, 2021
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Publication number: 20190376948
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 12, 2019
    Inventors: Bruce R. Yacyshyn, Mary E. Yacyshyn
  • Patent number: 10433708
    Abstract: An industrial operation having a system for remotely investigating and monitoring chemical reactions and structural and environmental conditions within the components of the industrial operation. The system includes a capsule having cameras within the capsule that operates to acquire data which is communicated to a monitor and relates to structural, environmental, chemical and/or fluid conditions within the components of the industrial operation.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 8, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Publication number: 20190242872
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Application
    Filed: March 29, 2019
    Publication date: August 8, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Patent number: 10295527
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 21, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Publication number: 20170261492
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 14, 2017
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn